favezelimab (MK-4280)

News alerts, weekly reports and conference planners

Company:

Agenus, Merck (MSD)

Drug class:

LAG-3 inhibitor

Related drugs:

TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials pembrolizumab + MK-4280 Sensitive : C3	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials pembrolizumab + MK-4280 Sensitive : C3
PD-L1 expression	Solid Tumor	PD-L1 expression	Solid Tumor	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials pembrolizumab + MK-4280 Sensitive : C3	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials pembrolizumab + MK-4280 Sensitive : C3

Associations
(2)